Analyst Ratings For CTI BioPharma (NASDAQ:CTIC)
Today, Cann initiated coverage on CTI BioPharma (NASDAQ:CTIC) with a Outperform.
Some recent analyst ratings include
- 2/23/2018-Cann initiated coverage with a Outperform rating.
- 9/12/2017-Jefferies Group initiated coverage with a Buy rating.
- 8/29/2016-Piper Jaffray Companies Reiterated Rating of Neutral.
Recent Insider Trading Activity For CTI BioPharma (NASDAQ:CTIC)
CTI BioPharma (NASDAQ:CTIC) has insider ownership of 2.16% and institutional ownership of 46.16%.
- On 2/9/2018 Bvf Partners L P/Il, Major Shareholder, bought 5,634,108 with an average share price of $3.00 per share and the total transaction amounting to $16,902,324.00.
- On 2/9/2018 Value Fund L P Biotechnology, Insider, bought 6,333,333 with an average share price of $3.00 per share and the total transaction amounting to $18,999,999.00.
- On 9/29/2017 Richard L Love, Director, sold 14,600 with an average share price of $3.21 per share and the total transaction amounting to $46,866.00.
- On 6/24/2016 James A Bianco, CEO, sold 10,000 with an average share price of $0.37 per share and the total transaction amounting to $3,700.00.
- On 5/27/2016 James A Bianco, CEO, sold 10,000 with an average share price of $0.45 per share and the total transaction amounting to $4,500.00.
- On 4/29/2016 James A Bianco, CEO, sold 10,000 with an average share price of $0.52 per share and the total transaction amounting to $5,200.00.
- On 3/28/2016 James A Bianco, CEO, sold 10,000 with an average share price of $0.49 per share and the total transaction amounting to $4,900.00.
Recent Trading Activity for CTI BioPharma (NASDAQ:CTIC)
Shares of CTI BioPharma closed the previous trading session at with 3.759999990463257 shares trading hands.